DK1905457T3 - Farmaceutiske sammensætninger omfattende Src og/eller Yes samt anvendelse deraf - Google Patents

Farmaceutiske sammensætninger omfattende Src og/eller Yes samt anvendelse deraf

Info

Publication number: DK1905457T3
Authority: DK; Denmark
Prior art keywords: protein; src; yes; modified; nucleic acids
Prior art date: 1999-12-22

Application number

DK07020078.7T

Other languages

English (en)

Inventor

David A Cheresh

Brian Eliceiri

Robert Paul

Original Assignee

Scripps Research Inst

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1999-12-22

Filing date

2000-12-22

Publication date

2012-05-29

1999-12-22 Priority claimed from US09/470,881 external-priority patent/US6685938B1/en

2000-12-22 Application filed by Scripps Research Inst filed Critical Scripps Research Inst

2012-05-29 Application granted granted Critical

2012-05-29 Publication of DK1905457T3 publication Critical patent/DK1905457T3/da

Links

239000008194 pharmaceutical composition Substances 0.000 title 1
102000004169 proteins and genes Human genes 0.000 abstract 6
108090000623 proteins and genes Proteins 0.000 abstract 6
239000000203 mixture Substances 0.000 abstract 4
230000008728 vascular permeability Effects 0.000 abstract 4
102000039446 nucleic acids Human genes 0.000 abstract 3
108020004707 nucleic acids Proteins 0.000 abstract 3
150000007523 nucleic acids Chemical class 0.000 abstract 3
102000009076 src-Family Kinases Human genes 0.000 abstract 3
108010087686 src-Family Kinases Proteins 0.000 abstract 3
238000000034 method Methods 0.000 abstract 2
229940121649 protein inhibitor Drugs 0.000 abstract 2
239000012268 protein inhibitor Substances 0.000 abstract 2
JRZJKWGQFNTSRN-UHFFFAOYSA-N Geldanamycin Natural products C1C(C)CC(OC)C(O)C(C)C=C(C)C(OC(N)=O)C(OC)CCC=C(C)C(=O)NC2=CC(=O)C(OC)=C1C2=O JRZJKWGQFNTSRN-UHFFFAOYSA-N 0.000 abstract 1
QTQAWLPCGQOSGP-GBTDJJJQSA-N geldanamycin Chemical compound N1C(=O)\C(C)=C/C=C\[C@@H](OC)[C@H](OC(N)=O)\C(C)=C/[C@@H](C)[C@@H](O)[C@H](OC)C[C@@H](C)CC2=C(OC)C(=O)C=C1C2=O QTQAWLPCGQOSGP-GBTDJJJQSA-N 0.000 abstract 1
230000002401 inhibitory effect Effects 0.000 abstract 1
238000004519 manufacturing process Methods 0.000 abstract 1
230000003389 potentiating effect Effects 0.000 abstract 1
WYZWZEOGROVVHK-GTMNPGAYSA-N radicicol Chemical compound C/1=C/C=C/C(=O)CC2=C(Cl)C(O)=CC(O)=C2C(=O)O[C@H](C)C[C@H]2O[C@@H]2\1 WYZWZEOGROVVHK-GTMNPGAYSA-N 0.000 abstract 1
239000000126 substance Substances 0.000 abstract 1
229940121358 tyrosine kinase inhibitor Drugs 0.000 abstract 1
239000005483 tyrosine kinase inhibitor Substances 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/45—Transferases (2)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
- A01K67/0271—Chimeric vertebrates, e.g. comprising exogenous cells
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Immunology (AREA)
Epidemiology (AREA)
Rheumatology (AREA)
Environmental Sciences (AREA)
Cardiology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Gastroenterology & Hepatology (AREA)
Heart & Thoracic Surgery (AREA)
Dermatology (AREA)
Zoology (AREA)
Orthopedic Medicine & Surgery (AREA)
Physical Education & Sports Medicine (AREA)
Ophthalmology & Optometry (AREA)
Vascular Medicine (AREA)
Urology & Nephrology (AREA)
Hematology (AREA)
Cell Biology (AREA)
Pain & Pain Management (AREA)
Animal Husbandry (AREA)
Biodiversity & Conservation Biology (AREA)
Diabetes (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)

DK07020078.7T 1999-12-22 2000-12-22 Farmaceutiske sammensætninger omfattende Src og/eller Yes samt anvendelse deraf DK1905457T3 (da)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US09/470,881 US6685938B1 (en)	1998-05-29	1999-12-22	Methods and compositions useful for modulation of angiogenesis and vascular permeability using SRC or Yes tyrosine kinases
US53824800A	2000-03-29	2000-03-29
EP00990365A EP1250155B1 (en)	1999-12-22	2000-12-22	Angiogenesis and vascular permeability modulators and inhibitors

Publications (1)

Publication Number	Publication Date
DK1905457T3 true DK1905457T3 (da)	2012-05-29

Family

ID=27043259

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
DK00990365T DK1250155T3 (da)	1999-12-22	2000-12-22	Modulatorer og inhibitorer af angiogenese og vaskulær permeabilitet
DK07020078.7T DK1905457T3 (da)	1999-12-22	2000-12-22	Farmaceutiske sammensætninger omfattende Src og/eller Yes samt anvendelse deraf

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
DK00990365T DK1250155T3 (da)	1999-12-22	2000-12-22	Modulatorer og inhibitorer af angiogenese og vaskulær permeabilitet

Country Status (19)

Country	Link
EP (2)	EP1905457B1 (da)
JP (1)	JP2003518077A (da)
KR (1)	KR100813818B1 (da)
CN (1)	CN1434727A (da)
AT (2)	ATE392215T1 (da)
AU (1)	AU781444B2 (da)
BR (1)	BR0016547A (da)
CA (1)	CA2395136A1 (da)
CZ (1)	CZ304320B6 (da)
DE (1)	DE60038631T2 (da)
DK (2)	DK1250155T3 (da)
ES (2)	ES2303514T3 (da)
HU (1)	HU229628B1 (da)
NO (1)	NO20023036L (da)
PL (1)	PL356815A1 (da)
PT (2)	PT1905457E (da)
RU (1)	RU2271216C2 (da)
SK (1)	SK287575B6 (da)
WO (1)	WO2001045751A1 (da)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20030130209A1 (en) *	1999-12-22	2003-07-10	Cheresh David A.	Method of treatment of myocardial infarction
EP1315732B1 (en)	2000-08-25	2006-06-07	Sloan-Kettering Institute For Cancer Research	Radicicol and monocillin and their analogues and uses thereof
JP2006507021A (ja) *	2002-03-18	2006-03-02	メドトロニック・エイヴイイー・インコーポレーテッド	再狭窄の危険のある解剖学的部位へ抗増殖性組成物を送付するための医療用具
CN1681525A (zh) *	2002-07-12	2005-10-12	曹义海	一种抑制血管渗漏和组织水肿的方法
EP1413887A1 (en) *	2002-10-22	2004-04-28	Aventis Pharma S.A.	Inhibitors of Src kinase for use in Alzheimer's disease
WO2004056386A2 (en) *	2002-12-19	2004-07-08	To-Bbb Holding B.V.	Nucleic acids involved in blood-brain barrier control
GB0307333D0 (en) *	2003-03-29	2003-05-07	Astrazeneca Ab	Therapeutic agent
ATE481134T1 (de) *	2004-01-21	2010-10-15	Univ Emory	Zusammensetzungen und verwendung von tyrosinkinase-hemmern zur behandlung von pathogenen infektionen
US20060094682A1 (en)	2004-10-29	2006-05-04	Odyssey Thera, Inc.	Kinase inhibitors for the treatment of diabetes and obesity
JP2009521510A (ja) *	2005-12-23	2009-06-04	アルコン，インコーポレイテッド	眼への受容体チロシンキナーゼ阻害（ｒｔｋｉ）化合物の送達のための医薬製剤
DK2463297T3 (da) *	2006-05-22	2017-01-09	Univ California	Sammensætninger og fremgangsmåder til levering af oxygen
EP1862802B1 (en) *	2006-06-01	2008-12-10	Cellzome Ag	Methods for the identification of ZAP-70 interacting molecules and for the purification of ZAP-70
DE102007037008B4 (de) *	2007-08-06	2015-09-10	Siemens Aktiengesellschaft	Diagnosesubstanz zur Anwendung in einem Verfahren zur Bestimmung der Aggressivität eines Prostatatumors
CN102656153B (zh) *	2009-10-29	2015-02-18	延世大学校产学协力团	新型血管渗漏阻断剂
RU2419418C1 (ru) *	2009-11-16	2011-05-27	Федеральное государственное унитарное предприятие "Государственный научный центр "Научно-исследовательский институт органических полупродуктов и красителей" (ФГУП "ГНЦ "НИОПИК")	Состав для удаления содержимого из атеросклеротических отложений в артериях человека
US8557513B2 (en) *	2011-06-27	2013-10-15	Biocrine Ab	Methods for treating and/or limiting development of diabetes
WO2014152122A2 (en) *	2013-03-15	2014-09-25	Children's Medical Center Corporation	Methods of altering vascular permeability and uses thereof
CN105311645B (zh) *	2015-01-23	2018-11-30	中国人民解放军第二军医大学	胚胎fyn相关底物efs在防治肠道病毒71型感染中的应用
CN105288654B (zh) *	2015-01-23	2018-11-30	中国人民解放军第二军医大学	蛋白酪氨酸激酶fyn癌基因在防治肠道病毒71型感染中的应用

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4356167A (en)	1978-01-27	1982-10-26	Sandoz, Inc.	Liposome drug delivery systems
US5092885A (en)	1987-02-12	1992-03-03	The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services	Peptides with laminin activity
US5112946A (en)	1989-07-06	1992-05-12	Repligen Corporation	Modified pf4 compositions and methods of use
US5542935A (en)	1989-12-22	1996-08-06	Imarx Pharmaceutical Corp.	Therapeutic delivery systems related applications
US5580575A (en)	1989-12-22	1996-12-03	Imarx Pharmaceutical Corp.	Therapeutic drug delivery systems
US5192744A (en)	1990-01-12	1993-03-09	Northwestern University	Method of inhibiting angiogenesis of tumors
DE69108716T2 (de) *	1990-01-26	1995-08-17	Washington Research Foundation, Seattle, Wash.	Immunreaktivität gegenüber exprimierten aktivierten oncogenen zur diagnose und behandlung von bösartigen geschwülsten.
ATE130517T1 (de)	1990-08-08	1995-12-15	Takeda Chemical Industries Ltd	Intravaskulär embolisierendes mittel mit gehalt an einem die angiogenesis hemmenden stoff.
US5912170A (en) *	1991-03-07	1999-06-15	The General Hospital Corporation	Redirection of cellular immunity by protein-tyrosine kinase chimeras
US5753230A (en)	1994-03-18	1998-05-19	The Scripps Research Institute	Methods and compositions useful for inhibition of angiogenesis
GB9417366D0 (en) *	1994-08-26	1994-10-19	Prolifix Ltd	Cell cycle regulated repressor and DNA element
US5643599A (en)	1995-06-07	1997-07-01	President And Fellows Of Harvard College	Intracellular delivery of macromolecules
US5922697A (en) *	1996-10-02	1999-07-13	Warner-Lambert Company	Compounds, compositions and methods for inhibiting the binding of proteins containing an SH2 domain to cognate phosphorylated proteins
US6093740A (en) *	1997-04-30	2000-07-25	Eli Lilly And Company	Therapeutic treatment for skin disorders
EP0984930B1 (en) *	1997-05-07	2005-04-06	Sugen, Inc.	2-indolinone derivatives as modulators of protein kinase activity
US6723694B1 (en) *	1997-05-21	2004-04-20	The Children's Medical Center Corp.	Short peptides which selectively modulate intracellular signalling
US6420338B1 (en) *	1997-06-13	2002-07-16	New York University Medical Center	Inhibition of the Src kinase family pathway as a method of treating HBV infection and hepatocellular carcinoma
CN1278724A (zh) *	1997-10-06	2001-01-03	巴斯福股份公司	抑制酪氨酸激酶活性的茚并[1,2－c]吡唑衍生物
ATE506073T1 (de) *	1998-05-29	2011-05-15	Scripps Research Inst	Verfahren zur modulation der angiogenese mittels der tyrosin kinase src
TR200102278T2 (tr) *	1998-11-06	2001-12-21	Basf Aktiengesellschaft	Vasküler hiperpermeabilite oluşumunun önlenmesi.

2000
- 2000-12-22 CA CA002395136A patent/CA2395136A1/en not_active Abandoned
- 2000-12-22 AU AU27400/01A patent/AU781444B2/en not_active Ceased
- 2000-12-22 AT AT00990365T patent/ATE392215T1/de active
- 2000-12-22 CN CN00819151A patent/CN1434727A/zh active Pending
- 2000-12-22 RU RU2002119399/15A patent/RU2271216C2/ru not_active IP Right Cessation
- 2000-12-22 ES ES00990365T patent/ES2303514T3/es not_active Expired - Lifetime
- 2000-12-22 EP EP07020078A patent/EP1905457B1/en not_active Expired - Lifetime
- 2000-12-22 ES ES07020078T patent/ES2383763T3/es not_active Expired - Lifetime
- 2000-12-22 PL PL00356815A patent/PL356815A1/xx not_active Application Discontinuation
- 2000-12-22 SK SK849-2002A patent/SK287575B6/sk not_active IP Right Cessation
- 2000-12-22 DE DE60038631T patent/DE60038631T2/de not_active Expired - Lifetime
- 2000-12-22 DK DK00990365T patent/DK1250155T3/da active
- 2000-12-22 AT AT07020078T patent/ATE553782T1/de active
- 2000-12-22 WO PCT/US2000/035396 patent/WO2001045751A1/en not_active Ceased
- 2000-12-22 KR KR1020027008102A patent/KR100813818B1/ko not_active Expired - Fee Related
- 2000-12-22 JP JP2001546690A patent/JP2003518077A/ja active Pending
- 2000-12-22 BR BR0016547-6A patent/BR0016547A/pt not_active Application Discontinuation
- 2000-12-22 EP EP00990365A patent/EP1250155B1/en not_active Expired - Lifetime
- 2000-12-22 PT PT07020078T patent/PT1905457E/pt unknown
- 2000-12-22 CZ CZ2002-2156A patent/CZ304320B6/cs not_active IP Right Cessation
- 2000-12-22 HU HU0203957A patent/HU229628B1/hu not_active IP Right Cessation
- 2000-12-22 DK DK07020078.7T patent/DK1905457T3/da active
- 2000-12-22 PT PT00990365T patent/PT1250155E/pt unknown
2002
- 2002-06-21 NO NO20023036A patent/NO20023036L/no not_active Application Discontinuation

Also Published As

Publication number	Publication date
EP1905457B1 (en)	2012-04-18
ATE553782T1 (de)	2012-05-15
KR100813818B1 (ko)	2008-03-17
DK1250155T3 (da)	2008-08-25
DE60038631D1 (de)	2008-05-29
HU229628B1 (en)	2014-03-28
EP1250155A1 (en)	2002-10-23
EP1905457A1 (en)	2008-04-02
SK287575B6 (sk)	2011-03-04
RU2271216C2 (ru)	2006-03-10
HUP0203957A3 (en)	2005-07-28
PT1905457E (pt)	2012-05-25
NO20023036L (no)	2002-07-22
EP1250155A4 (en)	2003-08-20
HUP0203957A2 (hu)	2003-03-28
CN1434727A (zh)	2003-08-06
AU781444B2 (en)	2005-05-26
NO20023036D0 (no)	2002-06-21
RU2002119399A (ru)	2004-02-27
AU2740001A (en)	2001-07-03
CZ304320B6 (cs)	2014-03-05
PL356815A1 (en)	2004-07-12
SK8492002A3 (en)	2002-11-06
ES2303514T3 (es)	2008-08-16
ES2383763T3 (es)	2012-06-26
KR20020063259A (ko)	2002-08-01
CA2395136A1 (en)	2001-06-28
WO2001045751A1 (en)	2001-06-28
JP2003518077A (ja)	2003-06-03
EP1250155B1 (en)	2008-04-16
DE60038631T2 (de)	2009-06-10
PT1250155E (pt)	2008-06-06
BR0016547A (pt)	2002-10-29
ATE392215T1 (de)	2008-05-15

Publication	Publication Date	Title
DK1905457T3 (da)	2012-05-29	Farmaceutiske sammensætninger omfattende Src og/eller Yes samt anvendelse deraf
HUP0100941A2 (hu)	2001-09-28	Kinolin, kinazolin és pirido-pirimidin-származékok és ezeket tartalmazó gyógyszerkészítmények
ATE275145T1 (de)	2004-09-15	Chinazolinderivate zur behandlung von tumoren
BR0116452A (pt)	2003-09-30	Composto, composição farmacêutica, uso de um composto
DK1638941T3 (da)	2010-10-11	Indazol-, benzisoxazol- og benzisothiazolkinaseinhibitorer
BR0008365A (pt)	2001-11-13	2-amino-6-anilino-purinas e o seu uso comomedicamento
BR0313176A (pt)	2005-06-14	Composições de pirazol úteis como inibidores de gsk-3
DE50213524D1 (de)	2009-06-18	Kationische sterolderivate, ph-sensitive liposomen diese umfassend und verfahren zur wirkstoffbeladung von liposomen
NO20002121L (no)	2000-05-09	Benzotiazol-protein-tyrosin-kinaseinhibitorer
ATE556713T1 (de)	2012-05-15	Omega-carboxyarylsubstituierte-diphenyl- harnstoffe als p38-kinasehemmer
DE60214198D1 (de)	2006-10-05	Isoxazolyl-pyrimidines als inhibitoren von src- und lck-protein-kinasen
ECSP055701A (es)	2005-05-30	Nuevos derivados de pirimidinamida y el uso de los mismos
MXPA04001328A (es)	2004-05-05	Productos en combinacion de derivados de 1,4-benzotiepina-1,1-dioxido con otros ingredientes activos, y su uso.
BRPI0407841A (pt)	2006-11-14	inibidores heterocìclicos de quinase
ATE279410T1 (de)	2004-10-15	3-aminopyrazole als inhibitoren von cyclinabhängigen kinasen
ATE213944T1 (de)	2002-03-15	Verwendung von immunomodulatoren
NO20006026L (no)	2001-01-24	Fremgangsmåter og blandinger for modulering av angiogenese ved bruk av tyrosin kinase SRC
NO20012428D0 (no)	2001-05-16	Substituerte kaprolaktamer, farmasöytiske sammensetninger som inneholder dem og deres anvendelse ved behandling av tumorer
NO20002408L (no)	2000-07-12	5-HT1F antagonister
DE50105650D1 (de)	2005-04-21	Verwendung von niedermolekularen heparin zur behandlung von osteoarthrose
DE60032161D1 (de)	2007-01-11	P-glycoproteine und ihre verwendungen
ATE314070T1 (de)	2006-01-15	Verwendung von pyridoindolonderivaten zur herstellung von antikrebsmitteln
DE60104577D1 (de)	2004-09-09	Verwendung von mono- und bifunktionalen (Per)Fluoropolyetherderivaten zur Behandlung von keramischen Werkstoffen
BRPI0416777A (pt)	2007-04-17	composto de piridinil metanona substituìdos por amino úteis no tratamento de disturbios da quinase
ATE272400T1 (de)	2004-08-15	Verwendung von tryptophan-derivaten zur spezifischen zytostatischen behandlung von serotonin-produzierenden tumoren